IMV Inc IMVIF

Quote from article on board member Michael Bailey

[LR6852]

Eventhough the focus is cancer, here's a quote from an article on board member Michael Bailey in the March 2021 Pharmaceutical Executive Magazine (pharmexec.com): 

Another silver lining of the pandemic has been the redevelopment of oncology therapies as COVID therapies. Though AVEO’s portfolio is not primed for this, the Canadian biotech IMV, for which Bailey is a board member, has a proprietary first-in-class delivery platform that offers a relevant application to COVID-19. “The company is actively developing a vaccine that we believe may overcome some of the resistance, durability, manufacturing, and distribution challenges that the first-generation COVID vaccines have seen,” says Bailey. “We’re encouraged and hopeful.”